Status:

NOT_YET_RECRUITING

Circadian Rhythm Deregulation in Patients With CAPS

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Cryopyrin Associated Periodic Syndrome

Familial Cold Urticaria

Eligibility:

All Genders

6+ years

Phase:

NA

Brief Summary

Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within ea...

Eligibility Criteria

Inclusion

  • --Inclusion Criteria:
  • Patient with CAPS group :
  • Patients aged 6 and over
  • Participant with CAPS confirmed by NLRP3 genetic analysis
  • Weight greater than or equal to 25 Kg
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Patient affiliated to a social security scheme
  • Control group (healthy participant):
  • Participant aged 6 and over
  • Weight greater than or equal to 25 Kg
  • Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol
  • Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Participant who has been informed of the study and has agreed to take part
  • Participant affiliated to a social security scheme
  • Exclusion Criteria :
  • Patient with CAPS group :
  • Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin).
  • Patients with sleep apnea syndrome
  • Patients working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Patient participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)
  • Control group (healthy participant):
  • Participants with a chronic illness (ALD beneficiaries)
  • Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin)
  • Participants working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Participant participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)

Exclusion

    Key Trial Info

    Start Date :

    September 1 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2028

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT06544018

    Start Date

    September 1 2025

    End Date

    November 1 2028

    Last Update

    June 25 2025

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Hôpital Femme-Mère-Enfant (HCL)

    Bron, France, 69677

    2

    Hôpital Claude Huriez (CHU de Lille)

    Lille, France, 59037

    3

    Hôpital de la Croix-Rousse (HCL)

    Lyon, France, 69004

    4

    Hôpital Edouard Herriot (HCL)

    Lyon, France, 69437